■异维A酸是痤疮的有效治疗方法,但可引起副作用,例如血脂和肝酶的变化。实验室监测在治疗期间至关重要,但是监测实践有所不同。
■本研究旨在探讨异维A酸治疗及其对沙特阿拉伯全血细胞计数的影响之间的关系,以改善患者的预后。
■该研究是在利雅得哈立德国王大学医院进行的回顾性队列研究,沙特阿拉伯,2016年1月至2020年12月。根据纳入和排除标准,随机选择515名患者进行研究。使用SPSS对数据进行分析,采用描述性统计和配对样本t检验对数据进行分析。
■在这项研究中,纳入515例患者。在这些参与者中,76.7%(n=395)为女性,23.3%(n=120)为男性。研究参与者的平均年龄为23.98±7.4岁,介于16至65岁之间。异维A酸的平均剂量为27.65±9.6mg/天,范围为10-60毫克/天。研究参与者的平均BMI为24.3±4.1kg/m2,范围为14.3至44.8kg/m2。关于异维A酸对实验室措施的影响,在血红蛋白测量中发现了显著的统计学差异(t=-3.379,p=0.001),血小板(t=-3.169,p=0.002),中性粒细胞(%)(t=3.107,p=0.002),总胆固醇(t=-13.017,p=0.000),AST(t=-6.353,p=0.000),ALT(t=-4.352,p=0.000),HDL(t=2.446,p=0.015),和LDL(t=-12.943,p=0.000)。然而,白细胞的测量没有显著的统计学差异,中性粒细胞(计数),或甘油三酯。在卡方分析和Fisher精确检验中,确定了BMI之间的相互作用,剂量,以及异常实验室结果的性别,参与者BMI和异常HDL测量值之间存在显著交互作用(p=0.006).此外,异维A酸剂量(小于30毫克/天或30毫克/天或更多)和异常中性粒细胞计数之间存在显着的相互作用(p=0.04),HDL测量异常(p=0.010),和异常的甘油三酯测量值(p=0.020)。此外,在参与者性别和异常血红蛋白测量之间发现了统计学上显著的相互作用(p=0.006),总胆固醇异常(p=0.016),AST测量异常(p=0.001),异常ALT测量值(p=0.000),HDL测量异常(p=0.000),和异常的甘油三酯测量(p=0.007)。
■总而言之,研究发现,异维A酸治疗对几种实验室措施有显著影响,包括血红蛋白,血小板,中性粒细胞,总胆固醇,AST,ALT,HDL,LDL。该研究还揭示了BMI之间的显着相互作用,剂量,性别,和异常的实验室结果。
UNASSIGNED: Isotretinoin is an effective treatment for acne but can cause side effects such as changes in blood lipids and liver enzymes. Laboratory monitoring is essential during treatment, but there is variation in monitoring practices.
UNASSIGNED: This study aims to investigate the relationship between isotretinoin therapy and its effects on complete blood count in Saudi Arabia to improve patient outcomes.
UNASSIGNED: The study was a retrospective cohort study conducted at King Khalid University Hospital in Riyadh, Saudi Arabia, between January 2016 and December 2020. Following the inclusion and exclusion criteria, 515 patients were randomly selected for the study. The data was analyzed using SPSS, and descriptive statistics and paired samples t-tests were employed to analyze the data.
UNASSIGNED: In this study, 515 patients were enrolled. Of these participants, 76.7% (n=395) were females and 23.3% (n=120) were males. The mean age of the study participants was 23.98±7.4 years and ranged between 16 and 65 years. The mean dose of Isotretinoin administered was 27.65±9.6 mg/day, with a range of 10-60 mg/day. The mean BMI of the study participants was 24.3±4.1 kg/m2, ranging from 14.3 to 44.8 kg/m2. Regarding the effect of Isotretinoin on laboratory measures, significant statistical differences were found in hemoglobin measurements (t=-3.379, p=0.001), platelets (t=-3.169, p=0.002), neutrophils (%) (t=3.107, p=0.002), total cholesterol (t=-13.017, p=0.000), AST (t=-6.353, p=0.000), ALT (t=-4.352, p=0.000), HDL (t=2.446, p=0.015), and LDL (t=-12.943, p=0.000). However, there were no significant statistical differences in the measurements of WBC, neutrophils (count), or triglycerides. In the Chi-square analysis and Fisher\'s Exact test to identify the interaction between BMI, dose, and gender on abnormal lab results, significant interaction was found between participants\' BMI and abnormal HDL measurements (p=0.006). Furthermore, there were significant interactions between Isotretinoin dose (either less than 30 mg/day or 30 mg/day or more) and abnormal neutrophil count (p=0.04), abnormal HDL measurements (p=0.010), and abnormal triglycerides measurements (p=0.020). Moreover, a statistically significant interaction was found between participants\' gender and abnormal hemoglobin measurements (p=0.006), abnormal total cholesterol (p=0.016), abnormal AST measurements (p=0.001), abnormal ALT measurements (p=0.000), abnormal HDL measurements (p=0.000), and abnormal triglycerides measurements (p=0.007).
UNASSIGNED: In conclusion, the study found that isotretinoin therapy has significant effects on several laboratory measures, including hemoglobin, platelets, neutrophils, total cholesterol, AST, ALT, HDL, and LDL. The study also revealed significant interactions between BMI, dose, gender, and abnormal lab results.